Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology · Myelodysplastic Syndromes

Standard Treatment Options for MDS

At a Glance

Treatment for Myelodysplastic Syndromes (MDS) is tailored to your specific risk category. Lower-risk MDS treatments focus on improving blood counts and quality of life, while higher-risk treatments aim to slow disease progression. A stem cell transplant is currently the only potential cure.

Treatment for Myelodysplastic Syndromes (MDS) is not “one size fits all.” Because the disease ranges from slow-moving (indolent) to aggressive, your treatment plan is built entirely around your risk category and your symptoms [1].

Treatment for Lower-Risk MDS

In lower-risk disease, the main goal is to improve your quality of life by raising your blood counts and reducing the need for blood transfusions [1].

  • Erythropoiesis-Stimulating Agents (ESAs): These are often the first treatment used for anemia. They act like a hormone signal to tell your bone marrow to make more red blood cells [2][3].
  • Luspatercept: If ESAs don’t work (or stop working), this injection can help red blood cells mature properly. It is especially effective for patients with the SF3B1 mutation or “ring sideroblasts” [4][5].
  • Imetelstat: Approved in mid-2024, this is a first-in-class medicine for patients who need frequent transfusions and haven’t responded to other treatments. It works by targeting an enzyme called telomerase [6][7].
  • Lenalidomide: This is the “gold standard” for a specific group of patients who have a missing piece of chromosome 5 (the del(5q) subtype) [8][9].

Treatment for Higher-Risk MDS

In higher-risk disease, the goal shifts toward slowing the progression of the disease and preventing it from turning into Acute Myeloid Leukemia (AML) [1].

  • Hypomethylating Agents (HMAs): Medications like azacitidine and decitabine are the backbone of treatment. They work by “turning on” genes that help blood cells mature and “turning off” the signals that help cancer cells grow [10][11].
  • Combination Therapies: Doctors are increasingly testing HMAs in combination with other drugs, such as venetoclax, to see if they can clear more cancer cells, especially as a “bridge” to a future transplant [12][13].

A Note on Side Effects: When starting powerful therapies like HMAs or lenalidomide, you may experience a phenomenon where your blood counts get worse before they get better. This is known as treatment-induced myelosuppression [14]. It can take several months for the bone marrow to clear out the diseased cells and begin producing healthy ones. Do not panic or prematurely abandon a working therapy without discussing these expected side effects with your doctor.

The Only Potential Cure: Allogeneic Stem Cell Transplant

For eligible patients with higher-risk disease, an allogeneic hematopoietic stem cell transplant (HSCT) is currently the only treatment that can potentially cure MDS [15].

  • How it works: Your diseased bone marrow is replaced with healthy stem cells from a donor.
  • The Timing Dilemma: For lower-risk patients, the risks of a transplant typically outweigh the benefits unless the disease shows signs of becoming more aggressive or contains high-risk mutations like TP53 [16][17]. Your doctor will carefully weigh your specific risk score before recommending this intensive procedure [18].

The Importance of Clinical Trials

Because we are still looking for more effective cures with fewer side effects, clinical trials are considered a vital part of MDS care [19]. Many of the “new” drugs mentioned above were only available through trials just a few years ago. Asking your doctor if a trial is right for you can often provide access to tomorrow’s treatments today.

Common questions in this guide

How does my MDS risk category affect my treatment plan?
Your risk category determines the primary goal of your treatment plan. For lower-risk MDS, the focus is managing symptoms like anemia and improving quality of life. For higher-risk MDS, treatment aims to slow disease progression and prevent it from turning into acute myeloid leukemia.
What are the standard treatments for lower-risk MDS?
Lower-risk MDS is often treated with therapies to boost healthy blood cells, such as erythropoiesis-stimulating agents (ESAs) or luspatercept. For patients with a specific genetic mutation called del(5q), the medication lenalidomide is considered the standard of care. Newer drugs like imetelstat may also be used if frequent blood transfusions are needed.
How do hypomethylating agents (HMAs) work for higher-risk MDS?
HMAs like azacitidine and decitabine are standard treatments for higher-risk MDS. They work by activating genes that help blood cells mature while blocking signals that allow cancer cells to grow. They are sometimes combined with other medications to help clear out diseased cells more effectively.
Can a stem cell transplant cure MDS?
An allogeneic stem cell transplant is currently the only potential cure for MDS. It involves replacing diseased bone marrow with healthy donor stem cells. Because it is an intensive procedure, it is typically reserved for eligible patients with higher-risk disease or high-risk genetic mutations.
Why might my blood counts drop when starting MDS treatment?
When starting powerful MDS therapies, your blood counts may temporarily get worse before they improve. This is an expected side effect called treatment-induced myelosuppression, as it takes time for your bone marrow to clear out the diseased cells and begin making healthy ones.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I currently in the 'Lower-Risk' or 'Higher-Risk' category, and how does that change my treatment goal (symptom management vs. disease control)?
  2. 2.Since I am anemic, should we start with an Erythropoiesis-Stimulating Agent (ESA), or am I a candidate for newer treatments like luspatercept or imetelstat?
  3. 3.If I have the del(5q) mutation, is lenalidomide the best first-line option for me?
  4. 4.What is the goal of starting a Hypomethylating Agent (HMA) like azacitidine, and how long does it usually take to see a response?
  5. 5.Am I a candidate for an allogeneic stem cell transplant, and if so, when is the ideal 'window' for me to have the procedure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.

    Sekeres MA, Taylor J

    JAMA 2022; (328(9)):872-880 doi:10.1001/jama.2022.14578.

    PMID: 36066514
  2. 2

    Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.

    Battaglia MR, Cannova J, Madero-Marroquin R, Patel AA

    Current treatment options in oncology 2024; (25(6)):752-768 doi:10.1007/s11864-024-01217-0.

    PMID: 38814537
  3. 3

    Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

    Kosmider O, Passet M, Santini V, et al.

    Haematologica 2016; (101(7)):e280-3 doi:10.3324/haematol.2016.142695.

    PMID: 27056923
  4. 4

    Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

    Fenaux P, Platzbecker U, Mufti GJ, et al.

    The New England journal of medicine 2020; (382(2)):140-151 doi:10.1056/NEJMoa1908892.

    PMID: 31914241
  5. 5

    How low risk are low risk myelodysplastic syndromes?

    DeZern AE, Dalton WB

    Expert review of hematology 2022; (15(1)):15-24 doi:10.1080/17474086.2022.2029698.

    PMID: 35041576
  6. 6

    Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

    Santini V, Zeidan AM, Van Eygen K, et al.

    Leukemia 2026; (40(2)):397-409 doi:10.1038/s41375-025-02831-z.

    PMID: 41526614
  7. 7

    Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.

    Hoff FW, Chung SS, Zeidan AM, Madanat YF

    JCO oncology practice 2026; (22(6)):961-967 doi:10.1200/OP-24-00910.

    PMID: 40763320
  8. 8

    Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

    Schuler E, Giagounidis A, Haase D, et al.

    Leukemia 2016; (30(7)):1580-2 doi:10.1038/leu.2015.340.

    PMID: 26668126
  9. 9

    Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

    Lian XY, Zhang ZH, Deng ZQ, et al.

    PloS one 2016; (11(11)):e0165948 doi:10.1371/journal.pone.0165948.

    PMID: 27824902
  10. 10

    Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?

    Bejar R

    NEJM evidence 2022; (1(10)):EVIDe2200165 doi:10.1056/EVIDe2200165.

    PMID: 38319862
  11. 11

    Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

    DeZern AE, Zeidan AM, Barnard J, et al.

    Leukemia & lymphoma 2017; (58(6)):1325-1331 doi:10.1080/10428194.2016.1246726.

    PMID: 27774847
  12. 12

    Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

    Zugasti I, Lopez-Guerra M, Castaño-Díez S, et al.

    Experimental hematology & oncology 2025; (14(1)):61 doi:10.1186/s40164-025-00652-5.

    PMID: 40287746
  13. 13

    Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.

    Braish JS, Montalban-Bravo G, Ravandi F, et al.

    Leukemia research 2025; (153()):107692 doi:10.1016/j.leukres.2025.107692.

    PMID: 40252309
  14. 14

    Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

    Zeidan AM, Stahl M, DeVeaux M, et al.

    Blood cancer journal 2018; (8(6)):55 doi:10.1038/s41408-018-0081-8.

    PMID: 29891916
  15. 15

    Advances in the management of higher-risk myelodysplastic syndromes: future prospects.

    Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, et al.

    Leukemia & lymphoma 2024; (65(9)):1233-1244 doi:10.1080/10428194.2024.2344061.

    PMID: 38712556
  16. 16

    Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines.

    DeFilipp Z, Ciurea SO, Cutler C, et al.

    Transplantation and cellular therapy 2023; (29(2)):71-81 doi:10.1016/j.jtct.2022.11.014.

    PMID: 36436780
  17. 17

    Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome.

    Novak P, Zabelina T, Wolschke C, et al.

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020; (26(11)):2047-2052 doi:10.1016/j.bbmt.2020.07.018.

    PMID: 32717435
  18. 18

    Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

    de Witte T, Bowen D, Robin M, et al.

    Blood 2017; (129(13)):1753-1762 doi:10.1182/blood-2016-06-724500.

    PMID: 28096091
  19. 19

    Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.

    Jabbour E, Faderl S, Sasaki K, et al.

    Cancer 2017; (123(4)):629-637 doi:10.1002/cncr.30383.

    PMID: 27741352

This page explains standard treatment options for MDS for educational purposes only. Always consult your hematologist or oncologist to determine the safest and most effective treatment plan for your specific risk category.

Get notified when new evidence is published on Myelodysplastic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.